CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., November 7, 2025 — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pioneering metabolic therapies for cardiometabolic and liver diseases, announced promising Phase 2 results from its M-ACCEL trial of HU6, an oral small molecule in development for Metabolic dysfunction-Associated Steatohepatitis (MASH). The data, presented as a Late-Breaker Oral Session at the 2025 AASLD Liver Meeting, demonstrated statistically significant reductions in liver fat, selective loss of fat mass with muscle preservation, and a favorable safety profile across all dose groups. These findings establish HU6 as a potential first-in-class metabolic modulator targeting the root cause of MASH through fat-selective energy expenditure.
Science Significance
The M-ACCEL Phase 2 study evaluated HU6 in over 450 adult patients with biopsy-confirmed or MRI-diagnosed MASH, including a large proportion with type 2 diabetes or obesity. HU6 acts as a Controlled Metabolic Accelerator (CMA) that selectively increases mitochondrial energy expenditure in fat tissue, reducing ectopic fat accumulation in the liver and visceral compartments without affecting lean muscle. Patients receiving HU6 at doses of 150 mg, 300 mg, and 450 mg daily achieved mean liver-fat reductions of 29–31 percent, compared with 6.7 percent for placebo (p < 0.005 for each). More than half of HU6-treated participants achieved a ≥ 30 percent reduction in hepatic fat content, a threshold linked to histologic improvement. Importantly, MRI analysis showed no muscle-mass loss, confirming HU6’s fat-selective metabolic mechanism. These results highlight HU6 as a next-generation oral therapeutic that can address both hepatic and systemic metabolic dysfunctions underlying MASH progression.
Regulatory Significance
The robust Phase 2 data strengthen Rivus’s position for pivotal Phase 3 development under global regulatory frameworks focused on liver-disease innovation. Conducted under Good Clinical Practice (GCP) and with oversight from independent safety monitoring committees, M-ACCEL’s design met all pre-specified endpoints aligned with FDA and EMA MASH-trial guidelines. The consistent results across dosing cohorts and metabolic profiles provide a strong foundation for accelerated regulatory discussions, including potential Fast Track or Breakthrough Therapy designation. Rivus intends to engage the FDA and EMA to define an efficient path toward registrational studies, potentially integrating non-invasive biomarkers as co-primary endpoints to reduce reliance on repeat liver biopsies. The trial’s transparent data-integrity structure reinforces the company’s compliance with cGxP standards governing data collection and reporting.
Business Significance
Advertisement
From a business perspective, M-ACCEL’s success marks a transformative inflection point for Rivus Pharmaceuticals. The data significantly enhance the commercial and partnership potential of the HU6 program, positioning Rivus as a strong contender in the competitive metabolic-liver-disease landscape. With MASH affecting over 25 million adults in the United States alone and no FDA-approved oral therapy available, HU6 could address a multi-billion-dollar global opportunity. The company’s CMA platform also opens therapeutic possibilities across related cardiometabolic disorders, including heart failure with preserved ejection fraction (HFpEF) and obesity-related insulin resistance. The promising Phase 2 outcome strengthens Rivus’s ability to attract strategic investors and biopharma collaborations, further extending its clinical and manufacturing infrastructure. These results reinforce investor confidence and support Rivus’s vision of becoming a leader in metabolic therapeutics innovation.
Patients’ Significance
For patients, HU6’s Phase 2 success offers tangible hope in a disease that remains largely untreated despite rising prevalence. MASH can progress to cirrhosis, liver failure, or hepatocellular carcinoma, and current treatments rely mostly on lifestyle modification and off-label therapies with limited efficacy. HU6’s ability to achieve meaningful liver-fat reduction, preserve muscle mass, and improve metabolic health represents a breakthrough approach that treats the metabolic origin of liver injury rather than simply managing symptoms. With its oral formulation and strong tolerability profile—minimal gastrointestinal events and no serious adverse drug reactions—HU6 may provide a convenient, long-term therapeutic option for patients at risk of advanced liver disease, improving quality of life and long-term outcomes.
Policy Significance
The Phase 2 M-ACCEL results align with global public-health priorities targeting obesity, diabetes, and non-alcoholic liver disease. Health agencies, including the U.S. FDA, European Medicines Agency (EMA), and World Health Organization, have identified MASH as an emerging epidemic requiring innovative, accessible therapies. HU6’s mechanism—enhancing energy metabolism safely—supports policies promoting non-invasive metabolic interventions over surgical or high-risk pharmacologic options. The findings also highlight the growing policy emphasis on precision-metabolism therapies, integrating liver and cardiovascular health within unified care models. As governments increase funding for metabolic-disease research, Rivus’s clinical achievements could shape future frameworks for regulatory fast-tracking, reimbursement, and patient access in liver-metabolism therapeutics.
Rivus Pharmaceuticals’ positive Phase 2 results for HU6 represent a major advance in the fight against metabolic liver disease. By combining rigorous science, regulatory compliance, and a patient-centered mission, the company has validated a novel therapeutic pathway that addresses both liver pathology and systemic metabolic dysfunction. These achievements underscore Rivus’s emergence as a next-generation biopharmaceutical innovator and strengthen its position in an evolving therapeutic field defined by precision, safety, and metabolic intelligence. As the company prepares for pivotal trials, HU6 stands poised to become a first-in-class oral therapy capable of transforming the landscape of MASH and redefining standards in metabolic health.
Source: Rivus Pharmaceuticals, Inc. press release
